Back to News
Market Impact: 0.35
UniQure's Ifezuntirgene Inilparvovec BLA Gets FDA Priority Review Acceptance
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The FDA accepted uniQure’s Biologics License Application for ifezuntirgene inilparvovec and granted it priority review. The agency’s target action date is May 1, 2027; the article reports no approval decision or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
QURE0.75
More News
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- How Trump’s trade policy is handing Asia to Beijing
- RA Capital Management sells $9.13M in Lenz Therapeutics shares
- Karyopharm stock rating cut to neutral by Rodman on bankruptcy
- Apple may try to increase revenue by doing…something with third-party AI apps